European Respiratory Society guidelines for the management of adult bronchiectasis

European Respiratory Journal

Volumn 50, Issue 3, 2017, Pages

  Polverino, Eva ^a   Goeminne, Pieter C ^b,c   McDonnell, Melissa J ^d,e,f   Aliberti, Stefano ^g   Marshall, Sara E ^h   Loebinger, Michael R ⁱ   Murris, Marlene ^j   Cantón, Rafael ^k   Torres, Antoni ^l   Dimakou, Katerina ^m   De Soyza, Anthony ^n,o   Hill, Adam T ^p   Haworth, Charles S ^q   Vendrell, Montserrat ^r   Ringshausen, Felix C ^s   Subotic, Dragan ^t   Wilson, Robert ⁱ   Vilaró, Jordi ^u   Stallberg, Bjorn ^v   Welte, Tobias ^s   Rohde, Gernot ^w   Blasi, Francesco ^g   Elborn, Stuart ^i,x   Almagro, Marta ^y   Timothy, Alan ^y   Ruddy, Thomas ^y   Tonia, Thomy ^z   Rigau, David ^aa   Chalmers, James D ^ab   more..

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b AZ Nikolaas   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY HOSPITAL GALWAY   (Ireland)

^e NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF MILAN   (Italy)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ ROYAL BROMPTON HOSPITAL   (United Kingdom)

^j SERVICE DE PNEUMOLOGIE   (France)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l UNIVERSITY OF BARCELONA   (Spain)

^m SOTIRIA GENERAL HOSPITAL   (Greece)

ⁿ NEWCASTLE UNIVERSITY   (United Kingdom)

^o FREEMAN HOSPITAL   (United Kingdom)

^p UNIVERSITY OF EDINBURGH   (United Kingdom)

^q PAPWORTH HOSPITAL   (United Kingdom)

^r HOSPITAL JOSEP TRUETA   (Spain)

^s HANNOVER MEDICAL SCHOOL   (Germany)

^t UNIVERSITY OF BELGRADE   (Serbia)

^u UNIVERSITAT RAMON LLULL   (Spain)

^v UPPSALA UNIVERSITY   (Sweden)

^w MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^x QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^y Embarc Bronchiectasis Patient Advisory Group   (United Kingdom)

^z UNIVERSITY OF BERN   (Switzerland)

^aa Iberoamerican Cochrane Center   (Spain)

^ab UNIVERSITY OF DUNDEE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; MUCOLYTIC AGENT; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ATYPICAL MYCOBACTERIUM; BACTERIAL LOAD; BRONCHIECTASIS; BRONCHODILATATION; COUGHING; DIARRHEA; DISEASE EXACERBATION; ERADICATION THERAPY; EXPIRATORY RESERVE VOLUME; HUMAN; INTERSTITIAL LUNG DISEASE; LOBECTOMY; LONG TERM CARE; LUNG CLEARANCE; PATHOGEN CLEARANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; PULMONARY REHABILITATION; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; SHORT COURSE THERAPY; SMOKING CESSATION; SPUTUM EXAMINATION; TREATMENT DURATION; CHRONIC DISEASE; DISEASE MANAGEMENT; EUROPE; LITERATURE; MEDICAL SOCIETY; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PHYSIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY CARE; SURGERY;

ADULT; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; BRONCHODILATOR AGENTS; CHRONIC DISEASE; DISEASE MANAGEMENT; EUROPE; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; PHYSICAL THERAPY MODALITIES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY THERAPY; REVIEW LITERATURE AS TOPIC; SOCIETIES, MEDICAL; SURGICAL PROCEDURES, OPERATIVE;

EID: 85030029653     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00629-2017     Document Type: Review

References (132)

1. Winter DH, Manzini M, Salge JM, et al. Aging of the lungs in asymptomatic lifelong nonsmokers: Findings on HRCT. Lung 2015; 193: 283-290.
2. Brozek JL, Akl EA, Compalati E, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelinesPart 3 of 3. The GRADE approach to developingrecommendations. Allergy 2011; 64: 1109-1116.
3. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: The significance and presentation of recommendations. J Clin Epidemiol 2013; 66: 719-725.
4. King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006; 100: 2183-2189.
5. Raghu G, King TE, Behr J, et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010; 35: 118-123.
6. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
7. Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186: 657-665.
8. Sheehan RE, Wells AU, Copley SJ, et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 2002; 20: 581-587.
9. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189: 576-585.
10. Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J 2016; 47: 1113-1122.
11. Kapur N, Masters IB, Chang AB. Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: What influences lung function stability?. Chest 2010; 138: 158-164.
12. Chalmers JD, Aliberti S, Polverino E, et al. The EMBARC European Bronchiectasis Registry: Protocol for an international observational study. ERJ Open Res 2016; 2: 00081-2015.
13. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: A long-term study assessing the factors influencing survival. Eur Respir J 2009; 34: 843-849.
14. McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis: An analysis of seven European cohorts. Thorax 2016; 71: 1110-1118.
15. Finch S, McDonnell MJ, Abo-Leyah H, et al. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc 2015; 12: 1602-1611.
16. Wilson CB, Jones PW, O'Leary CJ, et al. Systemic markers of inflammation in stable bronchiectasis. Eur Respir J 1998; 12: 820-824.
17. Tsang KW, Chan KN, Ho PL, et al. Sputum elastase in steady-state bronchiectasis. Chest 2000; 117: 420-426.
18. Chalmers JD, Moffitt KL, Suarez-Cuartin G, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med 2017; 195: 1384-1393.
19. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013; 55: 27-34.
20. Snijders D, Dominguez BF, Calgaro S, et al. Mucociliary clearance techniques for treating non-cystic fibrosis bronchiectasis: Is there evidence?. Int J Immunopathol Pharmacol 2015; 28: 150-159.
21. McDonnell MJ, Aliberti S, Goeminne PC, et al. Comorbidities and the risk of mortality in patients with bronchiectasis: An international multicentre cohort study. Lancet Respir Med 2016; 4: 969-979.
22. Du Q, Jin J, Liu X, et al. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease: A systematic review and meta-analysis. PLoS One 2016; 11: E0150532.
23. Navaratnam V, Muirhead CR, Hubbard RB, et al. Critical care admission trends and outcomes in individuals with bronchiectasis in the UK. QJM 2016; 109: 523-526.
24. Navaratnam V, Millett ER, Hurst JR, et al. Bronchiectasis and the risk of cardiovascular disease: A population-based study. Thorax 2017; 72: 161-166.
25. Ringshausen FC, de Roux A, Pletz MW, et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: A population-based study of disease burden and trends. PLoS One 2013; 8: E71109.
26. Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005; 12: 205-209.
27. Kwak HJ, Moon J-YY, Choi YW, et al. High prevalence of bronchiectasis in adults: Analysis of CT findings in a health screening program. Tohoku J Exp Med 2010; 222: 237-242.
28. Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: A population-based cohort study. Eur Respir J 2016; 47: 186-193.
29. Chang AB, Grimwood K, Mulholland EK, et al. Bronchiectasis in Indigenous children in remote Australian communities. Med J Aust 2002; 177: 200-204.
30. Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010; 138: 944-949.
31. Finklea JD, Khan G, Thomas S, et al. Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir Med 2010; 104: 816-821.
32. Goeminne PC, Nawrot TS, Ruttens D, et al. Mortality in non-cystic fibrosis bronchiectasis: A prospective cohort analysis. Respir Med 2014; 108: 287-296.
33. de la Rosa D, Martinez-Garcia MA, Olveira C, et al. Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence. Chron Respir Dis 2016; 13: 361-371.
34. Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease?. Heart Lung 2006; 35: 58-65.
35. O'Donnell AE, Barker AF, Ilowite JS, et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest 1998; 113: 1329-1334.
36. Barker AF, O'Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014; 2: 738-749.
37. Vendrell M, de Gracia J, Olveira C, et al. Normativa SEPAR: Diagnóstico y tratamiento de las bronquiectasias. Arch Bronconeumol 2008; 44: 629-640.
38. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: Suppl. 1, i1-i58.
39. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect 2011; 17: Suppl. 6, E1-59.
40. Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol 2013; 66: 726-735.
41. Alonso-Coello P, Schünemann HJ, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: A systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ 2016; 353: I2016.
42. Anwar GA, McDonnell MJ, Worthy SA, et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: A prospective observational cohort study. Respir Med 2013; 107: 1001-1007.
43. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007; 101: 1163-1170.
44. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277-1284.
45. Lonni S, Chalmers JD, Goeminne PC, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc 2015; 12: 1764-1770.
46. Greenberger PA. When to suspect and work up allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 2013; 111: 1-4.
47. Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 2012; 129: 280-291.
48. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
49. Lucas JS, Barbato A, Collins SA, et al. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur Respir J 2017; 49: 1601090.
50. Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130: 1503-1510.
51. Murray MP, Turnbull K, MacQuarrie S, et al. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009; 33: 312-317.
52. Orriols R, Roe J. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic broncial infection by Pseudomonas aeruginosa. Respir Med 1999; 93: 476-480.
53. McDonnell MJ, Jary HR, Perry A, et al. Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med 2015; 109: 716-726.
54. Orriols R, Hernando R, Ferrer A, et al. Eradication therapy against Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respiration 2015; 90: 299-305.
55. White L, Mirrani G, Grover M, et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012; 106: 356-360.
56. Goyal V, Chang AB. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. Cochrane Database Syst Rev 2014; CD010327.
57. Steele K, Greenstone M, Lasserson JA. Oral methyl-xanthines for bronchiectasis. Cochrane Database Syst Rev 2001; CD002734.
58. Lasserson T, Holt K. Oral corticosteroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst Rev 2001; CD002162.
59. Corless JA, Warburton CJ. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. Cochrane Database Syst Rev 2000; CD002174.
60. Kapur N, Chang AB. Oral non steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007; CD006427.
61. Pizzutto SJ, Upham JW, Yerkovich ST, et al. Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst Rev 2016; CD007525.
62. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: A 12 month study. Thorax 2005; 60: 239-243.
63. Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: A randomised controlled trial. Lancet Respir Med 2014; 2: 455-463.
64. Hernando R, Drobnic ME, Cruz MJ, et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int J Clin Pharm 2012; 34: 644-650.
65. Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: A systematic review. Eur Respir J 2014; 44: 382-393.
66. Gao Y, Guan W, Xu G, et al. Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis. PLoS One 2014; 9: E90047.
67. Shi ZL, Peng H, Hu XW, et al. Effectiveness and safety of macrolides in bronchiectasis patients: A meta-analysis and systematic review. Pulm Pharmacol Ther 2014; 28: 171-178.
68. Wu Q, Shen W, Cheng H, et al. Long-term macrolides for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis. Respirology 2014; 19: 321-329.
69. Zhuo GY, He Q, Xiang-Lian L, et al. Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: Meta-analysis of randomized controlled trials. Pulm Pharmacol Ther 2014; 30: 1-9.
70. Fan LC, Lu HW, Wei P, et al. Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: A meta-analysis of randomized controlled trials. BMC Infect Dis 2015; 15: 160.
71. Yang JW, Fan LC, Lu HW, et al. Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: A meta-analysis. Clin Respir J 2016; 10: 731-739.
72. Hnin K, Nguyen C, Carson K V, et al. Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. Cochrane Database Syst Rev 2015; 8: CD001392.
73. Currie DC, Garbett ND, Chan KL, et al. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med 1990; 76: 799-816.
74. Cymbala AA, Edmonds LC, Bauer MA, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005; 4: 117-122.
75. Drobnic ME, Suñé P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39: 39-44.
76. Murray MP, Govan JRW, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491-499.
77. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fi brosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-667.
78. Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial. Thorax 2013; 68: 812-817.
79. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The BLESS randomized controlled trial. JAMA 2013; 309: 1260-1267.
80. Altenburg J. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis. JAMA 2013; 309: 1251-1259.
81. De Diego A, Milara J, Martinez-Moragón E, et al. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. Respirology 2013; 18: 1056-1062.
82. Tabernero Huguet E, Gil Alaña P, Alkiza Basañez R, et al. Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection. Rev española Geriatr y Gerontol 2015; 50: 111-115.
83. Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189: 975-982
84. PROLONGED antibiotic treatment of severe bronchiectasis; a report by a subcommittee of the Antibiotics Clinical Trials (non-tuberculous) Committee of the Medical Research Council. Br Med J 1957; 2: 255-259.
85. Lourdesamy AI, Muthukumaru U. Efficacy of azithromycin in the treatment of bronchiectasis. Respirology 2014; 19: 1178-1182.
86. Liu J, Zhong X, He Z, et al. Effect of Low-Dose, long-term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis. Mediators Inflamm 2014; 2014: 708608.
87. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162: 481-485.
88. Hart A, Sugumar K, Milan SJ, et al. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2014; 5: CD002996.
89. Wilkinson M, Sugumar K, Milan SJ, et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev 2014; 5: CD001289.
90. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2002; 1: CD002996.
91. Nicolson CHH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012; 106: 661-667.
92. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011; 105: 1831-1835.
93. Bilton D, Daviskas E, Anderson D, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013; 144: 215-225.
94. Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: A randomised, controlled trial. Thorax 2014; 69: 1073-1079.
95. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J 2017; 49: 1700214.
96. Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: A roadmap to asthma control. Eur Respir J 2015; 46: 622-639.
97. Martínez-García MÁ, Soler-Cataluña JJ, Catalán-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest 2012; 141: 461-468.
98. Fan L-C, Liang S, Lu H-W, et al. Efficiency and safety of surgical intervention to patients with non-cystic fibrosis bronchiectasis: A meta-analysis. Sci Rep 2015; 5: 17382.
99. Hiramatsu M, Shiraishi Y, Nakajima Y, et al. Risk factors that affect the surgical outcome in the management of focal bronchiectasis in a developed country. Ann Thorac Surg 2012; 93: 245-250.
100. Hoffman E. The late results of the conservation of the apical segment of the lower lobe in resections for bronchiectasis. Thorax 1955; 10: 137-141.
101. Collis J. Fate of the lower apical segment in resections for bronchiectasis. Thorax 1953; 8: 323-325.
102. Tanaka H, Matsumura A, Okumura M, et al. Pneumonectomy for unilateral destroyed lung with pulmonary hypertension due to systemic blood flow through broncho-pulmonary shunts. Eur J Cardiothoracic Surg 2005; 28: 389-393.
103. Gourin A, Garzon AA. Operative treatment of massive hemoptysis. Ann Thorac Surg 1974; 18: 52-60.
104. Schneiter D, Meyer N, Lardinois D, et al. Surgery for non-localized bronchiectasis. Br J Surg 2005; 92: 836-839.
105. Zhang P, Zhang F, Jiang S, et al. Video-assisted thoracic surgery for bronchiectasis. Ann Thorac Surg 2011; 91: 239-243.
106. Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane database Syst Rev 2015; 11: CD008351.
107. Bradley J, Moran F, Greenstone M. Physical training for bronchiectasis. Cochrane Database Syst Rev 2002; CD002166.
108. Guimarães FS, Moço VJR, Menezes SLS, et al. Effects of ELTGOL and Flutter VRP1® on the dynamic and static pulmonary volumes and on the secretion clearance of patients with bronchiectasis. Rev Bras Fisioter 2012; 16: 108-113.
109. Nicolini A, Cardini F, Landucci N, et al. Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis. BMC Pulm Med 2013; 13: 21.
110. Eaton T, Young P, Zeng I, et al. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis. Chron Respir Dis 2007; 4: 23-30.
111. Naraparaju S, Vaishali K, Venkatesan P, et al. A comparison of the Acapella and a threshold inspiratory muscle trainer for sputum clearance in bronchiectasis-A pilot study. Physiother Theory Pract 2010; 26: 353-357.
112. Figueiredo PHS, Zin WA, Guimarães FS. Flutter valve improves respiratory mechanics and sputum production in patients with bronchiectasis. Physiother Res Int 2012; 17: 12-20.
113. Patterson JE, Bradley JM, Hewitt O, et al. Airway clearance in bronchiectasis: A randomized crossover trial of active cycle of breathing techniques versus acapella?. Respiration 2005; 72: 239-242.
114. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34: 1086-1092.
115. Faulkner J, Gerhard J, Stoner L, et al. Self-paced walking within a diverse topographical environment elicits an appropriate training stimulus for cardiac rehabilitation patients. Rehabil Res Pract 2012; 2012: 140871.
116. Lee AL, Hill CJ, Cecins N, et al. The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis - a randomised controlled trial. Respir Res 2014; 15: 44.
117. Zanini A, Aiello M, Adamo D, et al. Effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis: A retrospective analysis of clinical and functional predictors of efficacy. Respiration 2015; 89: 525-533.
118. Bradley J, Moran F, Greenstone M. Physical training for bronchiectasis. Cochrane Database Syst Rev 2002; CD002166.
119. Lee AL, Hill CJ, McDonald CF, et al. Pulmonary rehabilitation in individuals with non-cystic fibrosis bronchiectasis: A systematic review. Arch Phys Med Rehabil 2016; 774-782.e1.
120. Patterson JE, Bradley JM, Elborn JS. Airway clearance in bronchiectasis: A randomized crossover trial of active cycle of breathing techniques (incorporating postural drainage and vibration) versus test of incremental respiratory endurance. Chron Respir Dis 2004; 1: 127-130.
121. Gokdemir Y, Karadag-Saygi E, Erdem E, et al. Comparison of conventional chest physiotherapy and high-frequency chest wall oscillation in primary ciliary dyskinesia. Pediatr Pulmonol 2014; 49: 611-616.
122. Mandal P, Sidhu MK, Kope L, et al. A pilot study of pulmonary rehabilitation and chest physiotherapy versus chest physiotherapy alone in bronchiectasis. Respir Med 2012; 106: 1647-1654.
123. Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax 2005; 60: 943-948.
124. Liaw M-Y, Wang Y-H, Tsai Y-C, et al. Inspiratory muscle training in bronchiectasis patients: A prospective randomized controlled study. Clin Rehabil 2011; 25: 524-536.
125. Aliberti S, Masefield S, Polverino E, et al. Research priorities in bronchiectasis: A consensus statement from the EMBARC Clinical Research Collaboration. Eur Respir J 2016; 48: 632-647.
126. Wilson CB, Jones PW, O'Leary CJ, et al. Validation of the St. George's respiratory questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997; 156: 536-541.
127. Quittner AL, O'Donnell AE, Salathe MA, et al. Quality of Life Questionnaire-Bronchiectasis: Final psychometric analyses and determination of minimal important difference scores. Thorax 2015; 70: 12-20.
128. Martínez-García MA, Soler-Cataluña J-J, Perpiñá-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132: 1565-1572.
129. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J 2015; 45: 1446-1462.
130. Goeminne PC, Scheers H, Decraene A, et al. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: A retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012; 13: 21.
131. Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: A consensus definition for clinical research. Eur Respir J 2017; 49: 1700051.
132. Spinou A, Siegert RJ, Guan WJ, et al. The development and validation of the bronchiectasis health questionnaire. Eur Respir J 2017; 49: 1601532.